Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma
Latest Information Update: 20 Dec 2023
At a glance
- Drugs Bendamustine (Primary) ; Devimistat (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Adverse reactions
- 03 Apr 2023 Planned End Date changed from 1 Mar 2023 to 1 Dec 2023.
- 08 Apr 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
- 05 Jun 2019 Status changed from active, no longer recruiting to completed, according to a Rafael Pharmaceuticals media release.